高级检索
当前位置: 首页 > 详情页

Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Bladder Cancer After Radical Cystectomy

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Urology, West China Hospital, Sichuan University, Sichuan, People's Republic of China. [2]Institute of Urology, West China Hospital, Sichuan University, Sichuan, People's Republic of China.
出处:
ISSN:

关键词: lactate dehydrogenase albumin lactate dehydrogenase to albumin ratio bladder cancer prognosis

摘要:
Previous studies have suggested that the preoperative lactate dehydrogenase-to-albumin ratio (LAR) is correlated with survival in several cancers except bladder cancer (BCa). This study aimed to determine the prognostic value of the LAR in patients with urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC).A total of 595 UCB patients with RC in West China Hospital from December 2010 to May 2020 were enrolled. A receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value of the LAR. Kaplan-Meier curves and Cox regression analyses were applied to evaluate the association of the LAR with overall survival (OS) and recurrence-free survival. Independent factors in multivariate analyses were selected to construct nomograms. Calibration curves, ROC curves, concordance index (C-index) and decision curve analyses were used to evaluate the performance of the nomograms.The optimal cutoff value of the LAR was determined to be 3.8. Preoperative low LAR was associated with decreased OS (P < 0.001) and RFS (P < 0.001), especially in patients with ≥ pT2 disease. LAR was an independent factor for OS (hazard ratio [HR]: 1.719; P <0.001) and RFS (HR: 1.429; P = 0.012). The addition of the LAR into nomograms could result in better prediction performance. The areas under the curves of the nomograms were 0.821 and 0.801 for the prediction of 3-year OS and RFS, respectively. The C-indexes of the nomograms were 0.760 and 0.741 for the prediction of OS and RFS, respectively.The preoperative LAR is a novel and reliable independent prognostic biomarker for survival in UCB after RC.© 2023 Xu et al.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 3 区 免疫学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 免疫学
第一作者:
第一作者机构: [1]Department of Urology, West China Hospital, Sichuan University, Sichuan, People's Republic of China. [2]Institute of Urology, West China Hospital, Sichuan University, Sichuan, People's Republic of China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Urology, West China Hospital, Sichuan University, Sichuan, People's Republic of China. [2]Institute of Urology, West China Hospital, Sichuan University, Sichuan, People's Republic of China. [*1]Department of Urology, West China Hospital, Sichuan University, Sichuan, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号